The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...
E. Merck KG board of partners has announced the appointment of new CEOs to Merck KGaA’s executive board, aiding its ongoing ...
If and when approved by shareholders and regulators, the combined company will retain Pfizer's global operational headquarters ... will create a leading global pharmaceutical company with the ...
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva Pharmaceutical ...
In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDIâ„¢ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...